
UTHR · Nasdaq
United Therapeutics is a therapeutics company that sells medicines, including Tyvaso, and funds a development pipeline intended to produce additional treatments. The supplied evidence does not provide a segment breakdown, product-level revenue mix, customer categories, geographic exposure, or employee count, so the company’s revenue model can only be described generally as commercial pharmaceutical sales. Reported fiscal 2025 revenue was $3.2 billion and net income was $1.3 billion, up from $2.9 billion and $1.2 billion, respectively, in fiscal 2024. Its current scale is therefore billion-dollar annual revenue and profit generation.